Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. (MDGL) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for Madrigal Pharmaceuticals, Inc. (MDGL), featuring income statements, balance sheets, and cash flow data.
Madrigal Pharmaceuticals, Inc. (MDGL) Income Statement & Financial Overview
Analyze Madrigal Pharmaceuticals, Inc.’s MDGL earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| Revenue | $212.80M | $137.25M | $103.32M | $62.17M |
| Cost of Revenue | $9.06M | $4.51M | $3.44M | $2.15M |
| Gross Profit | $203.74M | $132.74M | $100.31M | $60.02M |
| Gross Profit Ratio | $0.96 | $0.97 | $0.97 | $0.97 |
| R&D Expenses | $54.08M | $44.17M | $25.65M | $68.74M |
| SG&A Expenses | $196.86M | $167.88M | $141.22M | $107.58M |
| Operating Expenses | $250.94M | $212.05M | $167.31M | $176.33M |
| Total Costs & Expenses | $260.004M | $216.56M | $170.32M | $178.48M |
| Interest Income | $8.23M | $9.37M | $11.08M | $13.02M |
| Interest Expense | -$3.26M | $3.30M | $3.50M | $3.68M |
| Depreciation & Amortization | $0.00 | $379000.00 | $363000.00 | $298000.00 |
| EBITDA | -$47.20M | -$69.56M | -$55.55M | -$102.99M |
| EBITDA Ratio | -$0.22 | -$0.51 | -$0.54 | -$1.66 |
| Operating Income | -$47.20M | -$79.31M | -$67.00M | -$116.30M |
| Operating Income Ratio | -$0.22 | -$0.58 | -$0.65 | -$1.87 |
| Other Income/Expenses (Net) | $4.92M | $6.07M | $7.58M | $9.34M |
| Income Before Tax | -$42.28M | -$73.24M | -$59.42M | -$106.96M |
| Income Before Tax Ratio | -$0.20 | -$0.53 | -$0.58 | -$1.72 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$42.28M | -$73.24M | -$59.42M | -$106.96M |
| Net Income Ratio | -$0.20 | -$0.53 | -$0.58 | -$1.72 |
| EPS | -$1.90 | -$3.32 | -$2.50 | -$4.92 |
| Diluted EPS | -$1.90 | -$3.32 | -$2.50 | -$4.92 |
| Weighted Avg Shares Outstanding | $22.21M | $22.09M | $21.27M | $21.75M |
| Weighted Avg Shares Outstanding (Diluted) | $22.21M | $22.09M | $21.27M | $21.75M |
Financial performance has remained strong, with revenue growing from $62.17M in Q3 2024 to $212.80M in Q2 2025. Gross profit continued to perform well, with margins at 96% in the latest quarter. Operating income reached -$47.20M in Q2 2025, holding a steady -22% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$47.20M. Net income rose to -$42.28M, keeping EPS at -$1.90. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan